News

According to Compendia, Oncomine Enterprise Edition builds upon the features of Oncomine Professional and Concepts editions by integrating the ability to securely view proprietary gene expression data in

South West RDA has reported the successful expansion of Devon-based pharmaceutical in the South West. Opal Healthcare has created a new company in the region as OI Sciences.

This randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial is being conducted in healthy adults. The company anticipates that trial results will be available by end of 2008. This US

The results demonstrated that PAC-113 is effective in the treatment of oral Candidiasis and compares favorably to the efficacy demonstrated by Nystatin, a current standard of care. The

Starting last quarter, Taami enrolled its first six patients and recently initiated the fifth participating hospital. The trial comprises two treatment groups and enrolls the most complex acute

The contract is anticipated to generate $1.5 to $2 million in revenues over the next 12-18 months. The contract includes technical transfer to support GMP manufacturing, process validation,

Jonathan Houssian, CEO and founder of RxElite, said: “This investment by NPIL Pharma will allow us to maintain our strong momentum in our Sevoflurane business through continued investment

The agreement provides Siad Healthcare with the right to sell in Italy and includes minimum purchase requirements. Pursuant to a previous agreement, Siad Healthcare was already selling SonaStar

True/Lok is a versatile, lightweight system designed to correct limb deformities, treat bone fractures and lengthen limbs using a simpler frame, according to Orthofix International. In addition to